Bliss GVS Pharma Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 31, 2025
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bliss GVS Pharma held its 40th AGM on July 31, 2025 via video conferencing, attended by 95 members and chaired by Mr. Nandkumar Chodankar. The company declared a final dividend of 50% (Re. 0.50 per share on a face value of Re. 1) for FY25. Management highlighted that ANDAs approved in FY25 for the U.S. market have been commercialized with volumes in line with budget, and commercial supplies to Canada and the UK have started from the Vevoor site. The company also plans to triple suppository manufacturing capacity at its USFDA and EU GMP-approved plant. Sub-Saharan Africa remains the largest geographic market, with expansion focus on the U.S., Canada, CIS countries, and the Middle East. Shareholders approved the audited financial statements, re-appointment of Dr. Vibha Gagan Sharma (retiring by rotation), and appointment of M/s. AVS & Associates as Secretarial Auditors. The statutory and secretarial auditors' reports were non-qualified.
The dividend declaration and positive business outlook (US ANDAs commercialization, new market entries, capacity expansion) signal confidence in growth, which may be viewed favorably by shareholders. The meeting was procedural with no contentious issues raised, keeping governance sentiment neutral-to-positive.